8:55 am Chair’s Opening Remarks

Exploring Novel Conjugation Technologies to Widen the Possibilities for Early Design & Discovery

9:00 am Filtering Out Which Conjugation Technology to Use to Enhance Your ADCs Efficacy

  • Paul Song Chief Scientific Officer, Genequantum Healthcare


  • Evaluating which novel conjugation technology is the simplest and easiest to use
  • Overviewing the novel conjugation technology landscape
  • Comparing novel conjugation technologies to traditional ones

9:30 am Conjugation Technology-Enabled Solutions Broaden the Scope of Conjugatable Drugs


  • Understanding how P5-labeling enables a rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies
  • Broadening the scope of drugs available for conjugation through novel Alco5-technology
  • Outlining a superior linker-payload platform for the efficient and steady delivery of various drugs with different modes of actions

10:00 am Morning Networking Break

11:00 am Next-Generation Hydrophilic Click-Chemistry – Veraxa’s Selectable Site-Specific Bioconjugation


  • Discussing the creation of selectable site-specific ADCs via incorporation of clickable non-canonical amino acids
  • Overviewing the development of Veraxa’s hydrophilic click chemistry for bioconjugation
  • Sharing Veraxa’s hydrophilic payload platform

11:30 am Harnessing Hinge-Region Disulfides for Homogenous DAR


  • Outlining site-specific conjugation using hinge-region disulfides
  • Developing a novel technology for homogenous DAR1
  • Assessing the application to multiple ADCs and next-generation conjugates

12:00 pm Networking Lunch

1:00 pm Highlighting How the Mode of Conjugation Impacts Challenges During Bioconjugation & Resulting ADC Behavior


  • Honing conjugation chemistries concerning the mAb to develop and advance conjugation technologies
  • Understanding the relationship between ADC design and thermal and chemical/ metabolic stability
  • Analyzing how to align linker and conjugation chemistries with each payload property

1:30 pm Roundtable Discussion: Assessing the Development of New Site-Specific Conjugation Platforms

  • Ning Zou Associate Director R&D Chemistry, Regeneron Pharmaceuticals Inc


  • Develop new conjugation platform for the generation of site-specific ADCs

2:00 pm Analyzing the Impact of Linker-Payload Technologies on Early-Phase Development

  • Olivier Marcq Vice President - Chemistry, Manufacturing & Controls, Tubulis


  • Understanding the impact of linker payload properties on ADC properties and linker payload and ADC manufacturing processes across development stages
  • Discussing the impact of linker payloads on analytical profile and analytical development
  • Reviewing the criticality of ADC properties and quality attributes for in vivo outcomes

2:30 pm Chair’s Closing Remarks

2:35 pm End of ADC Linker & Conjugation Summit